Ajay Major, MD, MBA
Assistant Professor, Medicine-Hematology

Website
Website
Photo
Medical School:
  • MD, Albany Medical College (2016)
Graduate School :
  • MBA, Union Graduate College (2013)
Undergraduate School:
  • BS, Union College (NY) (2012)
Residency:
  • University of Colorado, Internal Medicine (2019)
Fellowships:
  • University of Chicago Program, Hematology and Oncology (2022)
  • University of Chicago Program, Postdoctoral Fellow in Outcomes Research (2022)
Languages: English, Spanish
Department: Medicine-Hematology

Professional Titles

  • Assistant Professor of Medicine

Recognition & Awards

  • Chair of the ASH Trainee Council, American Society of Hematology (2021)
  • Chief Hematology/Oncology Fellow, The University of Chicago (2021)
  • Humanism and Excellence in Teaching Award, University of Colorado School of Medicine (2018)

Publications

  • Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Jan 12. [Epub ahead of print] PubMed PMID: 36642080
  • Major A, Porcu P, Haverkos BM. Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma. Cancers (Basel). 2023 Feb 21;15(5). PubMed PMID: 36900160
  • Derman BA, Chari A, Zonder J, Major A, Stefka AT, Jiang K, Karrison T, Jasielec J, Jakubowiak A. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 Feb 1. [Epub ahead of print] PubMed PMID: 36726221
  • Derman BA, Zonder JA, Reece D, Cole CE, Berdeja JG, Stefka AT, Major A, Kin A, Griffith KA, Jasielec J, Jakubowiak AJ. Phase 1/2 study of carfilzomib, pomalidomide, dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 Feb 10. [Epub ahead of print] PubMed PMID: 36763537
  • David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 Mar 25. [Epub ahead of print] PubMed PMID: 36965007
  • Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 Mar 24;:1-9. [Epub ahead of print] PubMed PMID: 36960939
  • Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood Adv. 2023 Apr 7. [Epub ahead of print] PubMed PMID: 37026796
  • Mian H, Wildes TM, Vij R, Pianko MJ, Major A, Fiala MA. Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. Blood Cancer J. 2023 May 10;13(1):76. PubMed PMID: 37164972
  • Kanack AJ, Singh B, George G, Gundabolu K, Koepsell SA, Abou-Ismail MY, Moser KA, Smock KJ, Green D, Major A, Chan CW, Wool GD, Reding M, Ashrani AA, Bayas A, Grill DE, Padmanabhan A. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol. 2022 May;97(5):519-526. PubMed PMID: 35132672
  • Lo AC, Major A, Super L, Appel B, Shankar A, Constine LS, Marks LJ, Kelly KM, Metzger ML, Buhtoiarov IN, Mauz-Körholz C, Costa ARS, Binkley MS, Flerlage J. Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW). Leuk Lymphoma. 2022 Mar 31;:1-4. [Epub ahead of print] PubMed PMID: 35357263
  • Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD Jr, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJ. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 Jul 21. [Epub ahead of print] PubMed PMID: 35862034
  • Major A, Kline J, Karrison TG, Fishkin PAS, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K, Besien KV, Rapoport AP, Smith SM. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 Jul 1;107(7):1608-1618. PubMed PMID: 34320785
  • Major A, Wright R, Hlubocky FJ, Smith SM, Prochaska MT. Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance. Leuk Lymphoma. 2022 Sep 18;:1-9. [Epub ahead of print] PubMed PMID: 36120910
  • Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 Jan 20;139(3):413-423. PubMed PMID: 34570876
  • Major A, Palese M, Ermis E, James A, Villarroel M, Klussmann FA, Hessissen L, Geel J, Khan MS, Dalvi R, Sullivan M, Kearns P, Frazier AL, Pritchard-Jones K, Nakagawara A, Rodriguez-Galindo C, Volchenboum SL. Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage. JCO Glob Oncol. 2022 Feb;8:e2100266. PubMed PMID: 35157510
  • Velazquez AI, Durani U, Weeks LD, Major A, Reynolds R, Kumbamu A, Das DG, Murphy MC, Henry E, Lee AI, Marshall AL. Impact of COVID-19 on Hematology-Oncology Fellowship Programs: A Quantitative and Qualitative Survey Assessment of Fellowship Program Directors. JCO Oncol Pract. 2022 Apr;18(4):e551-e563. PubMed PMID: 35015586
  • Ornoff DM, Balaban E, Major A, Berry A, Young E. The Missing Factor(s): Disseminated Amyloidosis Causing Coagulopathy Refractory to Plasma Transfusion. Am J Med. 2022 Jun;135(6):721-723. PubMed PMID: 35134365
  • Major A, Carll T, Chan CW, Christenson C, Aldarweesh F, Wool GD, Cohen KS. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE). J Clin Apher. 2022 Feb;37(1):117-121. PubMed PMID: 34672380
  • Major A, Cliff ERS, Ermann DA, Durani U, Russler-Germain DA. Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. EJHaem. 2022 Aug;3(3):930-935. PubMed PMID: 36051026
  • Durani U, Major A, Velazquez AI, May J, Nelson M, Zheng Z, Hall AG, Alam ST, Reynolds R, Thompson JC, Kumbamu A, Das DG, Murphy MC, Henry E, Lee AI, Marshall AL, Wun T, Weeks LD. Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. JCO Oncol Pract. 2022 Apr;18(4):e586-e599. PubMed PMID: 34990292
  • Major A, Jakubowiak A, Derman B. Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Jul 11. [Epub ahead of print] PubMed PMID: 35922273
  • Major A, Smith SM. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?. Clin Adv Hematol Oncol. 2021 Nov;19(11):698-709. PubMed PMID: 34807015
  • Major A, Williams JG, McGuire WC, Floyd E, Chacko K. Removing Barriers: A Confidential Opt-Out Mental Health Pilot Program for Internal Medicine Interns. Acad Med. 2021 May 1;96(5):686-689. PubMed PMID: 33538479
  • Major A, Williams JG, Connors GR, McBeth L, Keniston A, Naderi R. Developing a Novel Resilience Curriculum for Internal Medicine Interns Using a Survey-Based Needs Assessment. J Gen Intern Med. 2021 May;36(5):1451-1453. PubMed PMID: 32901437
  • Major A, Recklitis CJ, Bober S. Providing Effective Mental Health Support for Oncology Health-Care Workers in the COVID-19 Era: Responding Quickly but Carefully. JNCI Cancer Spectr. 2021 Jun;5(3):pkab031. PubMed PMID: 34099997
  • Major A, Collins J, Craney C, Heitman AK, Bauer E, Zerante E, Stock W, Bishop MR, Jasielec J. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021 Jul;62(7):1765-1769. PubMed PMID: 33559517
  • Bracken RC, Major A, Paul A, Ostherr K. Reflective Writing about Near-Peer Blogs: A Novel Method for Introducing the Medical Humanities in Premedical Education. J Med Humanit. 2021 Dec;42(4):535-569. PubMed PMID: 33871756
  • Ramesh S, Chokkara S, Shen T, Major A, Volchenboum SL, Mayampurath A, Applebaum MA. Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review. JCO Clin Cancer Inform. 2021 Dec;5:1208-1219. PubMed PMID: 34910588
  • Major A, Polite BN. Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will. Cancer J. 2020 Jul Aug;26(4):304-310. PubMed PMID: 32732673
  • Major A, Smith DE, Ghosh D, Rabinovitch R, Kamdar M. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. Cancer. 2020 Jan 1;126(1):189-201. PubMed PMID: 31509235
  • Major A, Hammes A, Schmidt MQ, Morgan R, Abbott D, Kamdar M. Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):39-46. PubMed PMID: 31761712
  • Major A, Cox SM, Volchenboum SL. Using big data in pediatric oncology: Current applications and future directions. Semin Oncol. 2020 Feb;47(1):56-64. PubMed PMID: 32229032
  • Acquaviva KD, Mugele J, Abadilla N, Adamson T, Bernstein SL, Bhayani RK, Büchi AE, Burbage D, Carroll CL, Davis SP, Dhawan N, Eaton A, English K, Grier JT, Gurney MK, Hahn ES, Haq H, Huang B, Jain S, Jun J, Kerr WT, Keyes T, Kirby AR, Leary M, Marr M, Major A, Meisel JV, Petersen EA, Raguan B, Rhodes A, Rupert DD, Sam-Agudu NA, Saul N, Shah JR, Sheldon LK, Sinclair CT, Spencer K, Strand NH, Streed CG Jr, Trudell AM. Documenting Social Media Engagement as Scholarship: A New Model for Assessing Academic Accomplishment for the Health Professions. J Med Internet Res. 2020 Dec 2;22(12):e25070. PubMed PMID: 33263554
  • Hudler A, Cataldo M, Major A, Lobo I. Needle in a Haystack: A Missed Case of Wound Botulism. Am J Med. 2019 Sep;132(9):e677-e678. PubMed PMID: 30951679
  • Major A, Jackson MW, Smith DE, Kamdar M, Rabinovitch R. Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. Leuk Lymphoma. 2019 May;60(5):1234-1243. PubMed PMID: 30501432
  • Major A, Chacko K. Routine vaccinations as a precipitant of adrenal crisis in adrenal insufficiency. Intern Med J. 2018 Mar;48(3):360-361. PubMed PMID: 29512322
  • Major A, Kamdar M. Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. Curr Treat Options Oncol. 2018 May 24;19(7):33. PubMed PMID: 29797086
  • Major A. Bourbon. JAMA Oncol. 2017 Oct 1;3(10):1309. PubMed PMID: 28542680
  • Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med. 2017 Jul 6;377(1):89-91. PubMed PMID: 28679093
  • Major A, Pan Z, Kamdar M. Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. Am J Hematol. 2017 Nov;92(11):1267-1268. PubMed PMID: 28370436
  • Major A, Anderson M. Not Just Skin Deep: Distant Metastases from Cutaneous Squamous Cell Carcinoma. Am J Med. 2017 Aug;130(8):e327-e328. PubMed PMID: 28344135
  • Major A. To bully and be bullied: harassment and mistreatment in medical education. Virtual Mentor. 2014 Mar 1;16(3):155-60. PubMed PMID: 24646841
View All (42 Total) View Less

Professional Memberships

  • American Society of Hematology (ASH), Appointed Committee Member
  • Alliance for Clinical Trials in Oncology, Member, Health Outcomes Committee
  • Global nLPHL One Working Group (GLOW), Founding Member and Chair of Patient-Reported Outcomes Working Group
  • Southwest Oncology Group (SWOG), Member, Lymphoma and Symptom Control & Quality of Life Committees
  • Lymphoma-Translational Health Outcomes Researchers (L-THORs), Founding Member and Chair
  • Patient-Reported Outcomes (PROs) Research Working Group, University of Colorado School of Medicine, Founding Member and Chair

Practice Locations

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Hematology, Board Certification (2022)
  • Medical Oncology, Board Certification (2022)
  • Internal Medicine, Board Certification (2019)
Conditions & Treatments
  • Cancers
  • Cancers - Lymphoma
  • Cancers - Myeloma
Care Philosophy
I am an assistant professor of medicine at the University of Colorado School of Medicine specializing in lymphoma and myeloma, and my outcomes and health services research focuses on patient-reported outcomes and how short- and long-term toxicities of treatment affect overall quality of life and survivorship in patients with blood cancers.

Public Speaking
Yes

General Information

Medical Schools:
  • MD, Albany Medical College (2016)
Graduate Schools:
  • MBA, Union Graduate College (2013)
Undergraduate Schools:
  • BS, Union College (NY) (2012)
Residency Programs:
  • University of Colorado, Internal Medicine (2019)
Fellowships:
  • University of Chicago Program, Hematology and Oncology (2022)
  • University of Chicago Program, Postdoctoral Fellow in Outcomes Research (2022)
Languages: English, Spanish
Department: Medicine-Hematology
SOM Resources
CU Resources
Contact Us
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;